Si-Wu-Tang and its constituents promote mammary duct cell proliferation by up-regulation of HER-2 signaling

Menopause

Volumn 13, Issue 6, 2006, Pages 967-976

  Chang, Chun Ju ^a   Chiu, Jen Hwey ^a,b   Tseng, Ling Ming ^a,b   Chang, Chuan Hsiung ^a   Chien, Tsu Ming ^a   Chen, Chien Chih ^c   Wu, Chew Wun ^b   Lui, Wing Yiu ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b Veterans General Hospital   (Taiwan)

^c NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

Author keywords

AKT; Breast cancer; ERK; HER 2; Menopause; Si Wu Tang

Indexed keywords

ANGELICA SINENSIS EXTRACT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FERULIC ACID; LIGUSTICUM CHUANXIONG EXTRACT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUTRALIZING ANTIBODY; PAEONIA LACTIFLORA EXTRACT; PHOSPHATIDYLINOSITOL 3 KINASE; PLANT EXTRACT; PROTEIN KINASE B; REHMANNIAE PREPARATA EXTRACT; SI WU TANG; TRYPAN BLUE; UNCLASSIFIED DRUG;

ANGELICA SINENSIS; ARTICLE; BREAST CANCER; BREAST DUCT; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; CHINESE MEDICINE; CONTROLLED STUDY; DOSE RESPONSE; FEEDBACK SYSTEM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGUSTICUM CHUANXIONG; MEDICINAL PLANT; MENOPAUSE; MITOGENESIS; PAEONIA; PROTEIN PHOSPHORYLATION; REHMANNIAE PREPARATA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; ESTROGEN RECEPTOR ALPHA; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; MAMMARY GLANDS, HUMAN; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLANT EXTRACTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 33751064405     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000227025.96686.8b     Document Type: Article

References (41)

1. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93:824-842.
2. Gradishar WJ. Tamoxifen - what next? Oncologist 2004;9:378-384.
3. Molassiotis A, Scott JA, Kearney N, et al. Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer 2006;14:260-267.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
6. Tindle HA, Davis RB, Phillips RS, Eisenberg DM. Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med 2005;11:42-49.
7. Hickey M, Saunders CM, Stuckey BG. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. Lancet Oncol 2005;6:687-695.
8. Zhang H, Shen P, Cheng Y. Identification and determination of the major constituents in traditional Chinese medicine Si-Wu-Tang by HPLC coupled with DAD and ESI-MS. J Pharm Biomed Anal 2004;34:705-713.
9. Angelica sinensis [monograph]. Altern Med Rev 2004;9:429-433.
10. Dai Y, But PP, Chan YP, Matsuda H, Kubo M. Antipruritic and anti-inflammatory effects of aqueous extract from Si-Wu-Tang. Biol Pharm Bull 2002;25:1175-1178.
11. Hsu HY, Ho YH, Lin CC. Protection of mouse bone marrow by Si-Wu-Tang against whole body irradiation. J Ethnopharmacol 1996;52:113-117.
12. Lee SE, Oh H, Yang JA, et al. Radioprotective effects of two traditional Chinese medicine prescriptions: Si-Wu-Tang and Si-Jun-Zi-Tang. Am J Chin Med 1999;27:387-396.
13. Amato P, Christophe S, Mellon PL. Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause 2002;9:145-150.
14. Lau CB, Ho TC, Chan TW, Kim SC. Use of dong quai (Angelica sinensis) to treat peri- or postmenopausal symptoms in women with breast cancer: is it appropriate? Menopause 2005;12:734-740.
15. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-153.
16. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A 1986;83:2496-2500.
17. Chiu JH, Kao HL, Wu LH, Chang HM, Lui WY. Prediction of relapse or survival after resection in human hepatomas by DNA flow cytometry. J Clin Invest 1992;89:539-545.
18. Lay IS, Chiu JH, Shiao MS, Lui WY, Wu CW. Crude extract of Salvia miltiorrhiza and salvianolic acid B enhance in vitro angiogenesis in murine SVR endothelial cell line. Planta Med 2003;69:26-32.
19. Bodinet C, Freudenstein J. Influence of marketed herbal menopause preparations on MCF-7 cell proliferation. Menopause 2004;11:281-289.
20. Chan RY, Chen WF, Dong A, Guo D, Wong MS. Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng. J Clin Endocrinol Metab 2002;87:3691-3695.
21. Eum HA, Lee WY, Kim SH, et al. Anti-inflammatory activity of CML-1: an herbal formulation. Am J Chin Med 2005;33:29-40.
22. Liu L, Ning ZQ, Shan S, et al. Phthalide lactones from Ligusticum chuanxiong inhibit lipopolysaccharide-induced TNF-α production and TNF-α-mediated NF-κβ activation. Planta Med 2005;71:808-813.
23. Chor SY, Hui AY, To KF, et al. Anti-proliferative and proapoptotic effects of herbal medicine on hepatic stellate cell. J Ethnopharmacol 2005;100:180-186.
24. Hou YZ, Zhao GR, Yuan YJ, Zhu GG, Hiltunen R. Inhibition of rat vascular smooth muscle cell proliferation by extract of Ligusticum chuanxiong and Angelica sinensis. J Ethnopharmacol 2005;100:140-144.
25. Lee SC, Kwon YS, Son KH, Kim HP, Heo MY. Antioxidative constituents from Paeonia lactiflora. Arch Pharm Res 2005;28:775-783.
26. Leem K, Kim H, Boo Y, et al. Effects of Paeonia lactiflora root extracts on the secretions of monocyte chemotactic protein-1 and -3 in human nasal fibroblasts. Phytother Res 2004;18:241-243.
27. Yang HO, Ko WK, Kim JY, Ro HS. Paeoniflorin: an antihyperlipidemic agent from Paeonia lactiflora. Fitoterapia 2004;75:45-49.
28. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343-2346.
29. Stoica GE, Franke TF, Moroni M, et al. Effect of estradiol on estrogen receptor-α gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 2003;22:7998-8011.
30. Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor α in breast cancer cells. Clin Cancer Res 2004;10:3621-3628.
31. Fernando RI, Wimalasena J. Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol Biol Cell 2004;15:3266-3284.
32. Lewis JS, Vijayanathan V, Thomas TJ, et al. Activation of cyclin D1 by estradiol and spermine in MCF-7 breast cancer cells: a mechanism involving the p38 MAP kinase and phosphorylation of ATF-2. Oncol Res 2005;15:113-128.
33. Arpino G, Green SJ, Allred DC, et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. Clin Cancer Res 2004;10:5670-5676.
34. Gutierrez MC, Detre S, Johnston S, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005;23:2469-2476.
35. Alum A, Yoon Y, Westerhoff P, Abbaszadegan M. Oxidation of bisphenol A, 17β-estradiol, and 17α-ethynyl estradiol and byproduct estrogenicity. Environ Toxicol 2004;19:257-264.
36. Menendez JA, Oza BP, Colomer R, Lupu R. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Int J Oncol 2005;26:1507-1515.
37. Chang EJ, Lee WJ, Cho SH, Choi SW. Proliferative effects of flavan-3-ols and propelargonidins from rhizomes of Drynaria fortunei on MCF-7 and osteoblastic cells. Arch Pharm Res 2003;26:620-630.
38. Nakagawa Y, Suzuki T. Metabolism of 2-hydroxy-4-methoxybenzophenone in isolated rat hepatocytes and xenestrogenic effects of its metabolites on MCF-7 human breast cancer cells. Chem Biol Interact 2002;139:115-128.
39. Blair RM, Fang H, Branham WS, et al. The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxicol Sci 2000;54:138-153.
40. Beckmann MW, Jap D, Djahansouzi S, et al. Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates. Oncology 2001;60:199-206.
41. Chang CJ, Chiu JH, Tseng LM, et al. Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells. Eur J Clin Invest 2006;36:588-596.